伏立康唑（UK-109,496）、伊曲康唑和两性霉素B对烟曲霉临床分离株的体外活性比较。
Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
作者信息
Cuenca-Estrella M, Rodríguez-Tudela J L, Mellado E, Martínez-Suárez J V, Monzón A
机构信息
Unidad de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
出版信息
J Antimicrob Chemother. 1998 Oct;42(4):531-3. doi: 10.1093/jac/42.4.531.
Voriconazole was compared with amphotericin B and itraconazole by a modification of the NCCLS microdilution reference method for yeasts against 62 clinical isolates of Aspergillus fumigatus. MICs of voriconazole were slightly lower than those of amphotericin B and itraconazole. The MIC of voriconazole at which 90% of isolates were inhibited was 1 mg/L and the MIC range was 0.25-2 mg/L. Voriconazole is a new antifungal agent with potential for use in the treatment of A. fumigatus infections.
通过对美国国家临床实验室标准委员会（NCCLS）针对酵母菌的微量稀释参考方法进行改进，将伏立康唑与两性霉素B和伊曲康唑进行比较，以检测其对62株烟曲霉临床分离株的抗菌活性。伏立康唑的最低抑菌浓度（MIC）略低于两性霉素B和伊曲康唑。90%的分离株被抑制时伏立康唑的MIC为1mg/L，MIC范围为0.25 - 2mg/L。伏立康唑是一种新型抗真菌药物，具有用于治疗烟曲霉感染的潜力。
Zotero 插件